Salcaprozate

Oral peptide delivery has long been considered a near-impossible frontier—enzymatic degradation, intestinal barriers, and near-zero membrane permeability have historically blocked almost every peptide candidate before it reached patients. Salcaprozate sodium (SNAC) reshapes this landscape from the excipient level. SNAC functions as an intestinal permeation enhancer: by locally buffering gastric pH to approximately 5, it inhibits pepsin activity, promotes monomerization of co-administered peptides, and markedly enhances passive transcellular transport—boosting oral bioavailability of co-formulated peptides by roughly 100-fold. This mechanism elevates SNAC from a conventional excipient to the core enabling technology of next-generation oral peptide drug delivery platforms, with primary applications spanning type 2 diabetes (oral GLP-1 therapies), osteoporosis, oral heparin, and insulin formulation programs.

SNAC's market trajectory is tightly coupled to the explosive growth of oral GLP-1 formulations. The SNAC-for-semaglutide sub-segment was valued at approximately USD 13 million in 2024 and is projected to reach USD 21.8 million by 2032 (CAGR ~7.9%). On a broader SNAC ingredient market basis, 2024 revenues are estimated at around USD 3.6 billion, potentially approaching USD 7.8 billion by 2031 (CAGR ~12.7%). The competitive landscape is dominated by Indian producers (Dr. Reddy's, Apothecon) and a rapidly expanding cohort of Chinese manufacturers (Hainan Poly Pharm, Suzhou Tianma, Sichuan Pukang, Jiangsu Southeast Nanomaterials, among others), with Chinese players now accounting for roughly 15% of global supply. Demand for pharmaceutical-grade SNAC (≥99% purity) is set to intensify as generic companies build oral GLP-1 pipelines ahead of upcoming patent windows.

SNAC technology originates from Emisphere's proprietary Eligen™ delivery platform, which Novo Nordisk licensed and incorporated into oral semaglutide tablets (Rybelsus®)—approved by the FDA in September 2019 as the world's first oral GLP-1 receptor agonist. The product is available in 3 mg, 7 mg, and 14 mg once-daily tablets. Following EMA and PMDA approvals, Rybelsus received NMPA approval in China in January 2025 for glycemic control in adults with type 2 diabetes. On the patent side, Rybelsus's key formulation patents covering SNAC-enabled oral GLP-1 compositions are set to expire in 2031 and 2034, with select claims extending to 2039—leaving the generics window firmly closed for now. Within China, several domestic manufacturers have completed CDE API registrations for SNAC, though high-purity GMP-grade supply remains concentrated among a small number of qualified producers. (Data as of May 2025; please refer to the CDE official website for the latest updates.)

As oral peptide pipelines multiply, demand for high-purity, regulation-compliant SNAC reference standards and related impurity characterization materials is growing in step. CATO/佳途科技 supplies a comprehensive portfolio of Salcaprozate Sodium reference standards—covering process impurities, degradation products, and related substances—compliant with EP, FDA, and multi-jurisdictional regulatory frameworks. The majority of products are held in ready stock, with same-day dispatch for orders placed before 16:00, enabling rapid support for process development, quality research, and regulatory submission workflows.